1. More Than Meets the Eye

3. Program Goals

4. Importance of Histology and Genotyping in NSCLC

5. Importance of Histology and Genotyping in NSCLC (cont)

6. CAP/IASLC Guidelines

7. Case Study 1

8. Case Study 1 (cont)

9. Treatment Selection in NSCLC: Tumor and Patient Considerations

10. Nab-Paclitaxel vs Solvent-Based Paclitaxel in Elderly Patients

11. Nivolumab: Checkmate 017

12. Ramucirumab: REVEL

13. Current Phase III Clinical Trials in Advanced Squamous Cell NSCLC (Selected)

14. Case Study 2: Non-squamous Pan-Negative NSCLC

15. Case Study 2: Biopsy Results

16. First-Line Treatment of Pan-Negative Non-squamous NSCLC

17. Emerging Agents for 2nd-line Treatment of Non-Squamous NSCLC

18. Abbreviations

19. Abbreviations (cont)

20. References

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)